ATE416791T1 - Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält - Google Patents
Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthältInfo
- Publication number
- ATE416791T1 ATE416791T1 AT01932810T AT01932810T ATE416791T1 AT E416791 T1 ATE416791 T1 AT E416791T1 AT 01932810 T AT01932810 T AT 01932810T AT 01932810 T AT01932810 T AT 01932810T AT E416791 T1 ATE416791 T1 AT E416791T1
- Authority
- AT
- Austria
- Prior art keywords
- cyclodextrin
- glycopeptide antibiotic
- composition containing
- disclosed
- pharmaceutical compositions
- Prior art date
Links
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 title abstract 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
- C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20117800P | 2000-05-02 | 2000-05-02 | |
| US21341500P | 2000-06-22 | 2000-06-22 | |
| US21341000P | 2000-06-22 | 2000-06-22 | |
| US21341700P | 2000-06-22 | 2000-06-22 | |
| US21314600P | 2000-06-22 | 2000-06-22 | |
| US21342800P | 2000-06-22 | 2000-06-22 | |
| US22672700P | 2000-08-18 | 2000-08-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE416791T1 true ATE416791T1 (de) | 2008-12-15 |
Family
ID=27569291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01932810T ATE416791T1 (de) | 2000-05-02 | 2001-05-01 | Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US6858584B2 (de) |
| EP (1) | EP1278549B1 (de) |
| JP (2) | JP4870314B2 (de) |
| CN (1) | CN1223378C (de) |
| AT (1) | ATE416791T1 (de) |
| AU (1) | AU2001259306A1 (de) |
| BR (1) | BR0110530A (de) |
| CA (2) | CA2726789A1 (de) |
| DE (1) | DE60136926D1 (de) |
| ES (1) | ES2316445T3 (de) |
| SI (1) | SI1278549T1 (de) |
| WO (1) | WO2001082971A2 (de) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE416791T1 (de) | 2000-05-02 | 2008-12-15 | Theravance Inc | Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält |
| UA75083C2 (uk) | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
| TWI312785B (en) * | 2001-08-24 | 2009-08-01 | Theravance Inc | Process for preparing vancomycin derivatives |
| TWI275594B (en) | 2001-08-24 | 2007-03-11 | Theravance Inc | Process for preparing vancomycin phosphonate derivatives |
| US7499410B2 (en) * | 2001-12-26 | 2009-03-03 | Cisco Technology, Inc. | Fibre channel switch that enables end devices in different fabrics to communicate with one another while retaining their unique fibre channel domain—IDs |
| US7599360B2 (en) * | 2001-12-26 | 2009-10-06 | Cisco Technology, Inc. | Methods and apparatus for encapsulating a frame for transmission in a storage area network |
| GB0206930D0 (en) * | 2002-03-23 | 2002-05-08 | Univ Durham | Method and apparatus for the formation of hydrophobic surfaces |
| US7406034B1 (en) | 2002-04-01 | 2008-07-29 | Cisco Technology, Inc. | Methods and apparatus for fibre channel frame delivery |
| US7616637B1 (en) | 2002-04-01 | 2009-11-10 | Cisco Technology, Inc. | Label switching in fibre channel networks |
| US7206288B2 (en) * | 2002-06-12 | 2007-04-17 | Cisco Technology, Inc. | Methods and apparatus for characterizing a route in fibre channel fabric |
| US7433326B2 (en) * | 2002-11-27 | 2008-10-07 | Cisco Technology, Inc. | Methods and devices for exchanging peer parameters between network devices |
| EP1641480A1 (de) * | 2003-05-27 | 2006-04-05 | Theravance, Inc. | Verwendung eines antimykotischen polyen-makrolids in kombination mit einem antibakteriellen glycopeptid-mittel |
| TWI342312B (en) * | 2003-10-22 | 2011-05-21 | Theravance Inc | Hydrochloride salts of a glycopeptide phosphonate derivative |
| EP1791544A4 (de) * | 2004-09-08 | 2007-09-12 | Chelsea Therapeutics Inc | Chinazolinderivate als metabolisch inerte antifolate |
| US7593324B2 (en) * | 2004-10-25 | 2009-09-22 | Cisco Technology, Inc. | Graceful port shutdown protocol for fibre channel interfaces |
| US7916628B2 (en) * | 2004-11-01 | 2011-03-29 | Cisco Technology, Inc. | Trunking for fabric ports in fibre channel switches and attached devices |
| MX2007006319A (es) | 2004-11-29 | 2007-07-25 | Univ Nagoya Nat Univ Corp | Derivados de monomeros de glicopeptico antibioticos. |
| US7649844B2 (en) * | 2004-12-29 | 2010-01-19 | Cisco Technology, Inc. | In-order fibre channel packet delivery |
| US20100204178A1 (en) | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
| US7795207B2 (en) | 2005-11-21 | 2010-09-14 | Harald Labischinski | Lipopeptide compositions |
| DE102005056194A1 (de) * | 2005-11-21 | 2007-07-12 | Combinature Biopharm Ag | Neue Lipopeptid Zusammensetzungen |
| NZ592293A (en) * | 2005-11-28 | 2012-10-26 | Verrow Pharmaceuticals Inc | Compositions comprising an oligosaccharide such as a cyclodextrin for reducing the nephrotoxicity of other drugs |
| US7658913B2 (en) * | 2005-11-28 | 2010-02-09 | Verrow Pharmaceuticals, Inc. | Compositions useful for reducing nephrotoxicity and methods of use thereof |
| KR20100132061A (ko) * | 2008-04-07 | 2010-12-16 | 첼시 쎄라퓨틱스, 인코포레이티드 | 항엽산제 화합물의 결정 염 형태 및 이의 제조 방법 |
| US8524691B2 (en) | 2008-08-13 | 2013-09-03 | The Medicines Company | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections |
| EA020490B1 (ru) | 2008-08-30 | 2014-11-28 | Тарганта Терапьютикс Корп. | Способ лечения бактериальной инфекции |
| ES2981472T3 (es) | 2009-04-28 | 2024-10-09 | Melinta Therapeutics Llc | Procedimientos para el tratamiento de infecciones bacterianas utilizando oritavancina |
| EP2451788A1 (de) * | 2009-07-08 | 2012-05-16 | Chelsea Therapeutics, Inc. | Stabile kristalline polymorphe des dikaliumsalzes aus (s) -2- {4- [2- (2, 4-diamin0-chinaz0lin-6-yl) -ethyl]-benzoylamino} -4-methylen -pentandisäure |
| WO2011056957A2 (en) * | 2009-11-06 | 2011-05-12 | Chelsea Therapeutics, Inc. | Enzyme inhibiting compounds |
| US20110237609A1 (en) * | 2010-03-29 | 2011-09-29 | Chelsea Therapeutics, Inc. | Antifolate compositions |
| US8658652B2 (en) | 2010-12-07 | 2014-02-25 | Chelsea Therapeutics, Inc. | Antifolate combinations |
| JP6617097B2 (ja) | 2013-03-15 | 2019-12-04 | メリンタ サブシディアリー コーポレーション | 抗生物質を用いて過体重および肥満の患者における感染を治療するための組成物 |
| LT3038616T (lt) | 2013-08-26 | 2023-05-25 | Melinta Therapeutics, Inc. | Bakteriemijos ir osteomielito gydymo būdai naudojant oritavanciną |
| US9697843B2 (en) | 2014-04-30 | 2017-07-04 | Qualcomm Incorporated | High band excitation signal generation |
| HUE069322T2 (hu) * | 2016-02-18 | 2025-03-28 | Melinta Therapeutics Llc | Oritavancin készítmények |
| US20200171124A1 (en) | 2016-04-15 | 2020-06-04 | Lupin Limited | Topical compositions for ophthalmic and otic use |
| CN107325159A (zh) * | 2016-04-29 | 2017-11-07 | 中国科学院上海药物研究所 | 一类万古霉素衍生物、其制备方法、药物组合物和用途 |
| US10729708B2 (en) * | 2016-05-09 | 2020-08-04 | Xellia Pharmaceuticals Aps | Stabilized glycopeptide antibiotic formulations |
| AU2018205823A1 (en) | 2017-01-03 | 2019-07-18 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto |
| CA3055474A1 (en) | 2017-03-28 | 2018-10-04 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto |
| JP7377791B2 (ja) | 2017-07-07 | 2023-11-10 | エピセントアールエックス，インコーポレイテッド | 治療剤の非経口投与のための組成物 |
| WO2019099525A1 (en) | 2017-11-15 | 2019-05-23 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing hyperbranched compounds as antibacterial scaffolds and methods pertaining thereto |
| CN107987131B (zh) * | 2017-11-16 | 2021-03-09 | 上海来益生物药物研究开发中心有限责任公司 | 一组具有抗耐药性细菌活性的化合物、其制备方法和应用 |
| EP3762039A4 (de) | 2018-03-06 | 2021-12-22 | The University of North Carolina at Chapel Hill | Stickoxidfreisetzende cyclodextrin als biologisch abbaubare antibakterielle gerüste und zugehörige verfahren |
| KR20210020889A (ko) | 2018-06-13 | 2021-02-24 | 디블라이 아게 | 응축된 트리아제핀 유도체의 제조 및 이의 bet 억제제로서 용도 |
| AU2019414421B2 (en) | 2018-12-28 | 2023-08-31 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto |
| US12257248B2 (en) | 2020-09-01 | 2025-03-25 | University Of South Florida | Bronchodilators for treating obstructive lung disease |
| US11433115B2 (en) | 2020-10-30 | 2022-09-06 | Somerset Therapeutics, Llc | Glycopeptide antibiotics liquid formulations and methods and uses thereof |
| EP4014969A1 (de) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Wässrige lösung |
| EP4014965A1 (de) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Wässrige lösung |
| UY40482A (es) | 2022-10-12 | 2024-04-30 | Hikma Pharmaceuticals Usa Inc | Composición líquida de dalbavancina. |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US77280A (en) * | 1868-04-28 | John l | ||
| US63916A (en) * | 1867-04-16 | Improvement in cotton peess | ||
| US229775A (en) * | 1880-07-06 | Eobeet h | ||
| US207797A (en) * | 1878-09-10 | Improvement in check-rein hooks | ||
| US73371A (en) * | 1868-01-14 | Robert moxley | ||
| US87494A (en) * | 1869-03-02 | William h | ||
| US4371673A (en) | 1980-07-21 | 1983-02-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble forms of retinoids |
| DE3372705D1 (en) | 1982-04-30 | 1987-09-03 | Takeda Chemical Industries Ltd | Pharmaceutical composition and its use |
| DE3346123A1 (de) | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4698327A (en) | 1985-04-25 | 1987-10-06 | Eli Lilly And Company | Novel glycopeptide derivatives |
| US4643987A (en) | 1985-08-14 | 1987-02-17 | Eli Lilly And Company | Modified glycopeptides |
| US4639433A (en) * | 1985-08-14 | 1987-01-27 | Eli Lilly And Company | Glycopeptide derivatives |
| US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| DE68906942T3 (de) | 1988-03-29 | 1999-05-12 | University Of Florida, Gainesville, Fla. | Pharmazeutische Zusammensetzungen für die parenterale Anwendung. |
| US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| US5196404B1 (en) | 1989-08-18 | 1996-09-10 | Biogen Inc | Inhibitors of thrombin |
| NZ236393A (en) | 1989-12-13 | 1992-05-26 | Lilly Co Eli | N-alkylated glycopeptide derivatives prepared from antibiotics a82846 series and pa-42867-a; pharmaceutical compositions |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9012663D0 (en) * | 1990-06-07 | 1990-08-01 | Erba Carlo Spa | Galenic formulations containing cyclodextrins |
| DE69128247T2 (de) | 1990-06-15 | 1998-03-19 | Majesty (Her) In Right Of Canada As Represented By The National Research Council Of Canada, Ottawa, Ontario | Thrombin-inhibitoren mit einer hirudin-ähnlichen sequenz |
| US5750509A (en) | 1991-07-29 | 1998-05-12 | Gruppo Lepetit S.P.A. | Amide derivatives of antibiotic A 40926 |
| YU48722B (sh) * | 1991-10-16 | 1999-07-28 | Schering Corporation | Postupak za dobijanje preparata soli lipofilnih oligosaharidnih antibiotika |
| IT1251751B (it) * | 1991-10-31 | 1995-05-23 | Sclavo Ricerca S R L | Metodo per la coltura di microrganismi dei generi helicobacter, campylobacter e arcobacter, utilizzando terreni di coltura contenenti ciclodestrine o metil-cellulosa o loro miscele |
| US5602112A (en) | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| US5324718A (en) | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
| JPH08503951A (ja) * | 1992-12-02 | 1996-04-30 | インサイト・ビジョン・インコーポレイテッド | シクロデキストリンとポリマーを用いた薬剤供給系 |
| CA2134753A1 (en) | 1993-03-08 | 1994-09-15 | Peter K. Chiang | Cyclodextrin-peptide compositions |
| JPH08507442A (ja) | 1993-03-12 | 1996-08-13 | セラテック，インコーポレイテッド | 組換えエプスタイン−バーウイルスタンパク質およびワクチンへの使用 |
| US6127337A (en) | 1993-10-25 | 2000-10-03 | National Research Council Of Canada | Bivalent thrombin inhibitors |
| US5840684A (en) | 1994-01-28 | 1998-11-24 | Eli Lilly And Company | Glycopeptide antibiotic derivatives |
| NZ270387A (en) | 1994-01-28 | 1996-11-26 | Lilly Co Eli | Glycopeptide antibiotic, its production and compositions thereof |
| SE510830C2 (sv) * | 1995-02-16 | 1999-06-28 | Pure Pulse Technologies Inc | Sätt att med god hållbarhet förpacka färskt kött i en förpackning av plast |
| US5919756A (en) | 1996-06-28 | 1999-07-06 | Eli Lilly And Company | Amides |
| DK0877600T3 (da) | 1996-08-09 | 2004-02-02 | Alcon Mfg Ltd | Konserveringssystem til farmaceutiske præparater indeholdende cyclodextrine |
| US5776912A (en) * | 1996-12-20 | 1998-07-07 | Schering Corporation | Lipophilic oligosaccharide antibiotic compositions |
| US5916873A (en) | 1997-04-17 | 1999-06-29 | Eli Lilly And Company | Teicoplanin derivatives |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| EP0889056B1 (de) * | 1997-07-01 | 2006-04-12 | Pfizer Products Inc. | Verfahren zur Herstellung von einem Cyclodextrin |
| GB2344713B (en) * | 1998-02-10 | 2003-05-07 | Furuno Electric Co | Display system |
| DK1140993T3 (da) | 1998-12-23 | 2003-10-06 | Theravance Inc | Glycopeptidderivater og farmaceutiske præparater indeholdende dem |
| EP1140999A1 (de) | 1998-12-23 | 2001-10-10 | Aventis Pasteur Limited | Chlamydia antigene, entsprechende dna fragmente und ihre verwendungen |
| DE19911097A1 (de) * | 1999-03-12 | 2000-09-14 | Basf Ag | Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen |
| AU4054900A (en) | 1999-04-02 | 2000-10-23 | Advanced Medicine East, Inc. | Desleucyl glycopeptide antibiotics and methods of making same |
| ATE416791T1 (de) * | 2000-05-02 | 2008-12-15 | Theravance Inc | Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält |
| US6770621B2 (en) * | 2000-05-02 | 2004-08-03 | Theravance, Inc. | Polyacid glycopeptide derivatives |
| UA82824C2 (uk) | 2000-06-21 | 2008-05-26 | К'Юбіст Фармасьютікалз, Інк. | Композиція і спосіб поліпшення перорального всмоктування протимікробних засобів |
| AU2001259816A1 (en) * | 2000-06-22 | 2002-01-02 | Advanced Medecine, Inc. | Polyhydroxy glycopeptide derivatives |
| WO2001098327A2 (en) | 2000-06-22 | 2001-12-27 | Theravance, Inc. | Glycopeptide carboxy-saccharide derivatives |
| UA75083C2 (uk) | 2000-06-22 | 2006-03-15 | Тераванс, Інк. | Похідні глікопептидфосфонатів |
| WO2001098326A2 (en) | 2000-06-22 | 2001-12-27 | Theravance, Inc. | Glycopeptide disulfide and thioester derivatives |
| US6872804B2 (en) | 2000-06-22 | 2005-03-29 | Theravance, Inc. | Glycopeptide disulfide and thioester derivatives |
| US6969706B1 (en) * | 2004-05-12 | 2005-11-29 | Allergan, Inc. | Preserved pharmaceutical compositions comprising cyclodextrins |
| US9216185B2 (en) * | 2008-07-11 | 2015-12-22 | Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon | Use of cilastatin to reduce nephrotatoxicity of various compounds |
-
2001
- 2001-05-01 AT AT01932810T patent/ATE416791T1/de not_active IP Right Cessation
- 2001-05-01 CA CA2726789A patent/CA2726789A1/en not_active Abandoned
- 2001-05-01 CN CNB018104746A patent/CN1223378C/zh not_active Expired - Lifetime
- 2001-05-01 JP JP2001579844A patent/JP4870314B2/ja not_active Expired - Lifetime
- 2001-05-01 CA CA2408008A patent/CA2408008C/en not_active Expired - Lifetime
- 2001-05-01 ES ES01932810T patent/ES2316445T3/es not_active Expired - Lifetime
- 2001-05-01 DE DE60136926T patent/DE60136926D1/de not_active Expired - Lifetime
- 2001-05-01 EP EP01932810A patent/EP1278549B1/de not_active Expired - Lifetime
- 2001-05-01 BR BR0110530-2A patent/BR0110530A/pt not_active Application Discontinuation
- 2001-05-01 US US09/846,893 patent/US6858584B2/en not_active Expired - Lifetime
- 2001-05-01 SI SI200130903T patent/SI1278549T1/sl unknown
- 2001-05-01 AU AU2001259306A patent/AU2001259306A1/en not_active Abandoned
- 2001-05-01 WO PCT/US2001/014000 patent/WO2001082971A2/en not_active Ceased
-
2004
- 2004-08-31 US US10/931,122 patent/US7067483B2/en not_active Expired - Lifetime
- 2004-08-31 US US10/930,585 patent/US7026288B2/en not_active Expired - Lifetime
-
2006
- 2006-04-25 US US11/410,597 patent/US7544364B2/en not_active Expired - Lifetime
-
2008
- 2008-04-03 JP JP2008097622A patent/JP2008231109A/ja active Pending
-
2009
- 2009-04-29 US US12/431,940 patent/US8158580B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1278549B1 (de) | 2008-12-10 |
| WO2001082971A3 (en) | 2002-05-23 |
| SI1278549T1 (sl) | 2009-04-30 |
| DE60136926D1 (de) | 2009-01-22 |
| US7026288B2 (en) | 2006-04-11 |
| CA2726789A1 (en) | 2001-11-08 |
| US7544364B2 (en) | 2009-06-09 |
| US20100081609A1 (en) | 2010-04-01 |
| US20050032676A1 (en) | 2005-02-10 |
| ES2316445T3 (es) | 2009-04-16 |
| US6858584B2 (en) | 2005-02-22 |
| WO2001082971A2 (en) | 2001-11-08 |
| AU2001259306A1 (en) | 2001-11-12 |
| US8158580B2 (en) | 2012-04-17 |
| US20020077280A1 (en) | 2002-06-20 |
| CN1441680A (zh) | 2003-09-10 |
| JP2008231109A (ja) | 2008-10-02 |
| JP2003531869A (ja) | 2003-10-28 |
| CA2408008A1 (en) | 2001-11-08 |
| BR0110530A (pt) | 2003-04-08 |
| CN1223378C (zh) | 2005-10-19 |
| US20050026820A1 (en) | 2005-02-03 |
| JP4870314B2 (ja) | 2012-02-08 |
| EP1278549A2 (de) | 2003-01-29 |
| US20060194717A1 (en) | 2006-08-31 |
| US7067483B2 (en) | 2006-06-27 |
| CA2408008C (en) | 2011-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE416791T1 (de) | Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält | |
| PL361341A1 (pl) | Nowa kompozycja farmaceutyczna | |
| YU46097A (sh) | Nova klasa estara i njihove farmaceutske smeše | |
| BR9710768A (pt) | Composto composi-Æo e processos para tratamento de infec-{es bacterianas em um mamifero hospedeiro com necessidade de tal tratamento e para prepara-Æo de 6-0-metileritromicina forma i | |
| BR0210122A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo | |
| PT759774E (pt) | Metodo para o tratamento de infeccoes bacterianas gram-negativas por administracao de um produto de proteina bactericida indutora da permeabilidade (bip) e de um antibiotico | |
| BR9714287A (pt) | Antibiótico cristalino designado solvato 6-o-metileritromicina forma 0, solvato de 6-o-metileritromicina forma 0, composição, processos para tratamento de infecções bacterianas em um mamìfero hospedeiro com necessidade de tal tratamento e para preparação de solvato de 6-o-metileritomicina a forma 0, 6-o-metileritromicina forma 0--etanolato, suspensão para administração oral, e, complexo de solvato de 6-o-metileritromicina a forma 0-carbÈmero. | |
| DK1347730T3 (da) | Rekombinante anti-CD30-antistoffer og anvendelser deraf | |
| BR0000003A (pt) | Azalidas e métodos de preparação das mesmas | |
| AP2004002952A0 (en) | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds. | |
| AR034343A1 (es) | Combinaciones farmaceuticas | |
| BG105600A (en) | 13-membered azalides and their use as antibiotic agents | |
| DE60041753D1 (de) | Arzneimittel zur behandlung von c. pneumoniae infektionen | |
| MXPA04000338A (es) | Diamindioles para tratamiento de enfermedad de alzheimer. | |
| BR0015698A (pt) | Composições e métodos para tratamento de doenças alérgicas | |
| EE200000587A (et) | Uued 15-lülilised ketoasaliidid, meetod nende valmistamiseks ning neid sisaldav farmatseutiline kompositsioon kasutamiseks bakternakkuste ravis | |
| MXPA03011521A (es) | Aminadioles para tratamiento de enfermedad de alzheimer. | |
| BR0002577A (pt) | Suspensões orais de trovafloxacina | |
| EP0932613A4 (de) | Expressionsblockierung von virulenten faktoren in s. aureus | |
| DK1434779T3 (da) | Tværbundne glycopeptid-cephalosporinantibiotika | |
| BR0211635A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento de um indivìduo sofrendo de ou propenso à doença de alzheimer | |
| IL113940A (en) | Synthetic peptides which are elastase inhibitors and pharmaceutical compositions for the treatment of neutrophil associated inflammatory disease containing said inhibitors | |
| MXPA03011502A (es) | Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer. | |
| MXPA04000337A (es) | Amindioles para tratamiento de enfermedad de alzheimer. | |
| ATE241640T1 (de) | Fusidinsäure-derivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |